Ypsomed Holding AG

Ypsomed Holding AG is a Swiss-based medical technology company specializing in the development and manufacturing of injection and infusion systems designed for self-medication. Celebrating its 40th anniversary in 2024, the company has established itself as a leading provider of innovative solutions for the administration of liquid medications, particularly in diabetes care. Through its flagship brands, such as mylife Diabetescare for consumers and Ypsomed Delivery Systems for business-to-business clients, Ypsomed offers an extensive portfolio including insulin pumps, autoinjectors, pen injectors, and associated supplies. These products are used in the treatment of diabetes, growth disorders, infertility, and other clinical conditions. Ypsomed operates globally, partnering with pharmaceutical and biotech companies as well as distributing directly to hospitals, pharmacies, and patients. Headquartered in Burgdorf, Switzerland, the organization manages a broad network of production facilities and subsidiaries, supported by around 2,600 employees. As a holding company structured under Swiss law, Ypsomed Holding AG oversees all group entities and plays a pivotal role in advancing self-care solutions in the medical device sector.